Anand, JP; Montgomery, D. Multifunctional opioid ligands In Delta Opioid Receptor Pharmacology and Therapeutic Applications; Jutkiewicz, EM, Ed., Springer Berlin Heidelberg, 20 Apr 2018; pp 21-51. 362 kB. https://doi.org/10.1007/164_2018_104
Johnson, MW; Griffiths, RR; Hendricks, PS; Henningfield, JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology, 1 Nov 2018, 142, 143-166. 2.5 MB. https://doi.org/10.1016/j.neuropharm.2018.05.012 #Buprenorphine
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #10
Ellis, CR; Kruhlak, NL; Kim, MT; Hawkins, EG; Stavitskaya, L. Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking PLOS ONE, 24 May 2018, 13 (5), e0197734. 5.5 MB. https://doi.org/10.1371/journal.pone.0197734 #Buprenorphine
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #Buprenorphine
Devereaux, AL; Mercer, SL; Cunningham, CW. DARK classics in chemical neuroscience: Morphine ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2395-2407. 3.0 MB. https://doi.org/10.1021/acschemneuro.8b00150 #9